Telomir Pharmaceuticals Reports New Osteosarcoma Research Findings, Validates Therapeutic Potential of Telomir-Zn.

Telomir Pharmaceuticals announced new research findings from Ohio State University demonstrating Telomir-Zn's inhibition of cell growth across human and canine osteosarcoma models. The study evaluated the compound's dose-dependent anti-tumor activity across three osteosarcoma cell line models. All three models showed growth inhibition at low drug concentrations, suggesting Telomir-Zn's therapeutic potential in osteosarcoma. Osteosarcoma is a devastating bone malignancy with limited treatment options and poor outcomes in both humans and large-breed dogs. The biological similarities between canine and human osteosarcoma make the canine model a clinically predictive disease model for translational research.